Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice-Reference-Cited by-同舟云学术

Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice

Published:2003-04 Issue:1 Volume:4 Page:28-38
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Jahanzeb Mohammad

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference62 articles.

1. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J Clin Oncol,1999

2. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002

3. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials;Mass;Proc Am Soc Clin Oncol,2000

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

5. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer;Osoba;J Clin Oncol,2002

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral vinorelbine: a narrative review;Cancer Nursing Practice;2018-03-08

2. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study;Breast Cancer Research and Treatment;2017-03-21

3. Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series;Journal of Oncology;2012

4. Trastuzumab and Vinorelbine as Highly Effective and Safe Therapy for HER-2-Overexpressing Metastatic Breast Cancer. A Single Institution Experience;Tumori Journal;2008-07

5. Oral Vinorelbine;Drugs;2007